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OBJECTIVES: To assess covariates that affect the duration of
pain relief doxepin oral rinse provided cancer patients with
painful oral mucositis. METHODS: Fifty consecutive patients
with oral mucositis due to head and neck radiation therapy 
participated in the original study. An examination of the mouth
was completed and oral mucositis scored using the Oral Mucosi-
tis Assessment Scale (OMAS) which assesses erythema severity
and ulceration size. Oral pain was assessed with a visual ana-
logue scale (VAS) prior to taking the rinse and then at ﬁve, 15,
30 minutes, one-hour, while continuing every half hour up to
three-hours, and at four-hours following rinsing. The time until
recurrence of pretest pain level was deﬁned as the time it took
for VAS pain scores to reach or exceed initial pain scores. 
Recurrence of pain relief was right censored at four-hours for
twenty patients; survival analysis was utilized to determine 
what factors were associated with recurrence of pain. RESULTS:
Signiﬁcant pain reduction was reported. Patients described, 
on average, a 55.6% reduction in pain after 15 minutes of
doxepin rinsing. Recurrence of pain was slow and signiﬁcant
reduction in pain from baseline continued at four hours (p <
0.0001). The hazard ratios from the Cox proportional hazards
model (p < 0.001) determined that holding all other variables
constant, an increase by one unit in either the baseline pain sever-
ity, the worst documented erythema score, or the relative reduc-
tion of pain at 15 minutes, decreased the rate of pain recurrence
at any time (t) by 45.3, 38.8, or 71.8% respectively. CONCLU-
SIONS: This research shows good results for doxepin oral rinse.
Mucositis patients who reported higher baseline pain, more
severe erythema, or larger relative reductions in pain after 15
minutes of rinsing, had a larger probability of extended pain
relief.
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OBJECTIVE: In the US, 18–30 year-olds (yo) have less health
insurance than any other age group. Because delays in diagnosis
may therefore be an explanation for slower progress in cancer
survival improvement in this age group, we compared health
insurance status with their time from onset of ﬁrst cancer
symptom to diagnosis (TDx). METHODS: From June, 2001 to
May, 2003, MDACC registered 270 newly-diagnosed 15–29
year-olds with acute leukemia, Hodgkin disease, non-Hodgkin
lymphoma, sarcomas, brain tumors and thyroid cancer. A total
of 235 had complete data on TDx, type of cancer, age, gender,
race/ethnicity, marital status, religion, and according to zipcode
of residence, median household income, population density and
urban-vs.-rural location. RESULTS: In multivariate analysis,
only the type of cancer and health insurance status were signif-
icantly correlated with TDx (p < 0.05). The log mean TDx in
patients with public or no health insurance was 6.3 weeks longer
than in patients with private insurance and 13.1 weeks longer
than in self-pay patients (p < 0.001). In six of seven evaluable
histologies, the log mean TDx was longer, by an average of 10.6
weeks, in patients with public vs. those with private insurance
(p < 0.05 in ﬁve histologies). In all four histologies evaluable for
stage, the log mean TDx was longer, by an average of 17.5
weeks, in patients with advanced stage than in those with local-
ized disease. CONCLUSIONS: Young adults with cancer with
inadequate health insurance are likely to have a delay in diag-
nosis and are at risk for a more advanced stage of disease. Health
insurance status appears to be a stronger determinant than other
parameters of socioeconomic status. As a factor contributing to
the relative lack of survival improvement in young adults with
cancer, lack of health insurance in this age group is a problem
that the United States can and should solve.
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OBJECTIVE: IV bisphosphonates are effective in reducing skele-
tal related events (SREs) and alleviating bone pain in breast
cancer patients with bone metastasis. However, these agents are
characterized by different efﬁcacy, administration time, and
costs. Formal analyses are therefore needed to understand their
overall economic value and budgetary impacts. We conducted a
formal economic analysis to compare the budgetary impacts of
these agents, from the UK NHS perspective. METHODS: A
Markov model was developed to simulate over a period of seven
years the survival and incidence of SREs for a hypothetical
cohort of 1000 patients receiving no treatment (NT) or monthly
injections of ibandronate (IBN), generic pamidronate (PA) or
zoledronic acid (ZA). Probabilities of SREs (extrapolated from
skeletal morbidity rates [SMR]) were obtained from published
clinical trials of each agent. Costs of drugs and their infusion and
cost of SREs were estimated from published sources. Survival
was identical across all groups (25 months). RESULTS: Based
on relative reduction of risk of SREs (ratio of SMR of bisphos-
phonate therapy vs. no therapy), the cumulative number of SREs
over the lifetime of the patients was lowest for ZA (3820 events),
followed by PA (4430), IBN (4890), and NT (6020). Total dis-
counted costs (which included drug costs, infusion administra-
tion costs, and cost of treating SREs) for the cohorts of 1000
patients were £2,457,000 lower for ZA than IBN, £1,160,000
lower than PA, and £556,000 lower than NT. Fifty and 75% of
these savings, respectively, occurred within the ﬁrst 12 and 24
months of the simulation. These ﬁndings were robust across
various sensitivity analyses. ZA was less costly and more effec-
tive than all other treatment options, and is therefore the eco-
nomically preferred option. CONCLUSIONS: Zoledronic acid
appears to be the most cost-effective and least costly IV bispho-
sphonate therapy.
